Abbott laboratories - direct investment history in Facet biotech corp

Filed on 2010-04-21 by Abbott Laboratories SEC CIK 1800 Form 4

Accession 0001104659-10-021021.txt Sec File: edgar/data/1800/0001104659-10-021021-index.htm

2010-04-21 Abbott Laboratories (CIK 1800) through Direct

Invested in Facet Biotech Corp bought 5980034 shares at $27 remaining shares owned 1000

Common Stock Facet Biotech Corp Fact Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f5 reflects all of the outstanding shares of facet not tendered in the offer, which may be deemed to have been acquired by abbott and the purchaser pursuant to the consummation of the merger. at the effective time of the merger, these shares were cancelled and ceased to exist.
f6 prior to the merger, abbott held 1,000 shares of the common stock, no par value per share, of the purchaser (the "purchaser shares"), which represented all of the issued and outstanding capital stock of the purchaser. at the effective time of the merger, each purchaser share was converted into one share of common stock of facet, as the surviving corporation of the merger, and as a result abbott acquired 100% of the equity interest of facet.


Filed on 2010-04-21 by Abbott Laboratories SEC CIK 1800 Form 4

Accession 0001104659-10-021021.txt Sec File: edgar/data/1800/0001104659-10-021021-index.htm

2010-04-20 Abbott Laboratories (CIK 1800) through Direct

Invested in Facet Biotech Corp bought 62652055 shares at $27.00 remaining shares owned 81909724

Common Stock Facet Biotech Corp Fact Transaction code: P Open market or private purchase of securities

f1 this form is a joint filing by abbott laboratories ("abbott") and amber acquisition inc., a wholly-owned subsidiary of abbott (the "purchaser").
f2 this form 4 relates to shares of common stock, par value $0.01 per share (the "common stock"), and the associated preferred stock purchase rights issued in connection with the rights agreement, dated as of september 7, 2009, as amended by the amendments thereto dated as of december 15, 2009, december 16, 2009 and march 9, 2010, by and between facet and mellon investor services llc (together with the common stock, the "shares"), of facet.
f3 reflects shares of facet acquired by the purchaser upon the exercise of the "top-up" option described in the tender offer statement on schedule to, as amended or supplemented, initially filed with the securities and exchange commission on march 23, 2010 by abbott and the purchaser (the "schedule to").
f4 following the exercise of the "top-up" option, facet was merged with and into the purchaser with facet surviving the merger as a wholly-owned subsidiary of abbott pursuant to a "short-form merger" under delaware law as described in the schedule to (the "merger"). at the effective time of the merger, these shares were cancelled and ceased to exist.


Filed on 2010-04-21 by Abbott Laboratories SEC CIK 1800 Form 3

Accession 0001104659-10-021020.txt Sec File: edgar/data/1800/0001104659-10-021020-index.htm

2010-04-20 Abbott Laboratories (CIK 1800) through Direct

Invested in Facet Biotech Corp remaining shares owned 19257669

Common Stock Facet Biotech Corp Fact

f1 this form is a joint filing by abbott laboratories ("abbott") and amber acquisition inc., a wholly-owned subsidiary of abbott (the "purchaser").
f2 this form 3 relates to shares of common stock, par value $0.01 per share (the "common stock"), and the associated preferred stock purchase rights issued in connection with the rights agreement, dated as of september 7, 2009, as amended by the amendments thereto dated as of december 15, 2009, december 16, 2009 and march 9, 2010, by and between facet and mellon investor services llc (together with the common stock, the "shares"), of facet.
f3 reflects shares of facet purchased upon the expiration of a tender offer commenced pursuant to the tender offer statement on schedule to, as amended or supplemented, initially filed with the securities and exchange commission on march 23, 2010 by abbott and the purchaser. amount includes 914,673 shares tendered through guaranteed delivery procedures.